文献速递银屑病与炎症性皮肤病

加拿大安大略省银屑病与银屑病关节炎患者死亡率及死因别死亡率趋势

Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada.
PubMed 文献 · J Am Acad Dermatol · 2020-10-21

该研究基于加拿大安大略省1996至2016年行政健康数据,比较银屑病及银屑病关节炎(PsA)患者与一般人群的全因和死因别死亡率。2016年识别出176,858例银屑病(2,524例死亡)和15,430例PsA(221例死亡)患者,其标准化超额死亡率分别为每1000人1.44和2.43。研究期间两组的标准化死亡率均下降约30%,但仍显著高于一般人群,主要死因为癌症、循环系统疾病和呼吸系统疾病。

要点

  • 银屑病和PsA患者标准化死亡率研究期间下降约30%,但仍显著高于一般人群。
  • 2016年银屑病和PsA患者标准化超额死亡率分别为每1000人1.44和2.43。
  • 银屑病和PsA患者前三位死因为癌症、循环系统疾病和呼吸系统疾病。

核心结论

  • 尽管银屑病治疗改善,银屑病和PsA患者的相对超额死亡率保持不变,2016年平均每1000例患者约1至2例额外死亡。

研究设计与样本

  • 基于人群的回顾性队列研究,使用加拿大安大略省1996至2016年行政健康数据,纳入成人居民。
  • 2016年识别银屑病患者176,858例(2,524例死亡)和PsA患者15,430例(221例死亡)。

主要发现

  • 银屑病患者标准化超额死亡率为每1000人1.44,PsA患者为每1000人2.43。
  • 研究期间两组标准化死亡率均下降约30%,但仍显著高于一般人群。
  • 银屑病和PsA患者主要死因为癌症、循环系统疾病和呼吸系统疾病。

临床怎么用

  • 皮肤科医生应关注银屑病和PsA患者的高死亡风险,尤其是癌症、循环系统疾病和呼吸系统疾病。
  • 尽管治疗进步,仍需对银屑病和PsA患者进行共病筛查和综合管理以降低超额死亡。

局限性

  • 研究无法根据疾病严重程度对患者进行分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past 2 decades. OBJECTIVE: To compare all-cause and cause-specific mortality rates in patients with psoriasis to the general population in Ontario, Canada, from 1996 to 2016. METHODS: We conducted a population-based, retrospective cohort study of adult residents using administrative health data. All-cause and cause-specific standardized mortality rates, standardized mortality ratios, and excess mortality rates were calculated. RESULTS: 176,858 (2,524 deaths) patients with psoriasis and 15,430 (221 deaths) patients with PsA were identified in 2016. Patients with psoriasis and PsA had standardized excess mortality rates of 1.44 and 2.43 per 1000 population, respectively. Standardized mortality rates decreased by approximately 30% over the study period in both disease groups but remained significantly elevated compared to the general population. The leading causes of death in psoriasis and PsA patients were cancer, circulatory disease, and respiratory conditions. LIMITATIONS: We were unable to classify patients according to disease severity. CONCLUSIONS: Despite improvements in psoriasis treatment, the relative excess mortality, which may be related to risk factors for psoriatic disease, remained unchanged, with an average of approximately 1 to 2 extra deaths per 1,000 patients in 2016.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Colaco K, Widdifield J, Luo J, et al. Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. J Am Acad Dermatol. 2020. PMID: 33096129. doi:10.1016/j.jaad.2020.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。